Summary:
Researchers demonstrated in lab-grown human brain cells and cortical organoids that boosting the activity of a single healthy gene copy can offset the cellular effects of autism-linked genetic mutations.
The study used a modified CRISPR technique targeting noncoding DNA enhancers for the CHD8 and SCN2A genes, safely normalizing tissue growth and neuronal electrical firing exclusively in mutated cells without causing toxic gene overexpression.
Key Facts:
- Targeting Regulatory “Dials”: Instead of editing faulty DNA directly, researchers used modified CRISPR activation aimed at cell-type-specific enhancers to naturally turn up expression of the remaining healthy gene copy for CHD8 and SCN2A.
- Restoring Growth and Electrical Function: In human cortical organoids and excitatory neuron models, boosting the healthy copy reversed abnormal brain tissue overgrowth in CHD8 mutants and restored normal electrical firing in SCN2A mutants.
- Mutation-Specific Safety: The intervention increased gene expression exclusively in cells carrying the autism-associated mutations, leaving healthy cell lines and neighboring genes completely unaffected while avoiding harmful overexpression.
Source: UCLA Health / Nature Neuroscience
Autism spectrum disorder (ASD) carries a substantial genetic component, with roughly 15% of genetic risk arising from de novo mutations, spontaneous genetic alterations that appear for the first time in a child rather than being inherited.
Many of these high-impact mutations result in haploinsufficiency, a biological state in which one copy of a critical developmental gene is disabled, leaving the remaining healthy copy unable to produce enough protein to sustain typical neurodevelopment.
While existing clinical interventions primarily manage behavioral and cognitive symptoms, developing gene therapies to correct the underlying molecular deficits has proven exceptionally challenging, largely because delivering extra copies of large genes or directly overexpressing them can cause severe cellular toxicity.
Now, in a study published in Nature Neuroscience, researchers at UCLA Health led by Dr. Daniel Geschwind and Dr. George Chen have unveiled a precision epigenomic strategy that sidesteps these hurdles.
Working in human stem cell-derived neurons and three-dimensional cortical organoids, the team used a modified CRISPR system to gently turn up the volume on the body’s own remaining healthy gene copy, nudging developing brain cells back toward typical trajectories.
Turning Up the Volume via DNA Enhancers
Rather than cutting DNA or inserting synthetic transgenes, the investigators utilized CRISPR activation (CRISPRa) directed at enhancers, specialized stretches of noncoding regulatory DNA that function like biological dimmer dials, dictating precisely when, where, and how strongly a target gene is expressed.
The team focused on two of the most prominent genes linked to autism and neurodevelopmental disorders:
- CHD8: A master chromatin-remodeling gene that regulates vast networks of downstream genes essential for early brain growth and cellular maturation.
- SCN2A: A gene encoding a critical voltage-gated sodium channel required for excitatory neurons to generate and propagate electrical action potentials.
By targeting endogenous enhancers rather than the gene promoters themselves, the researchers sought to keep gene activation strictly synchronized with natural, cell-type-specific developmental rhythms and prevent dangerous overshooting into gene overexpression.
“Many autism-linked mutations leave a person with one working copy of a gene instead of two,” explained senior author Dr. Daniel Geschwind, the Gordon and Virginia MacDonald Distinguished Professor of Human Genetics, Neurology, and Psychiatry at UCLA. “Our results show that, in human cell models, it’s possible to turn up that remaining copy and move cells back toward typical development. This is a key first step, and it gives us a new way to think about addressing the biology underlying these conditions.”
Reversing Organoid Overgrowth and Restoring Neural Firing
To test the therapeutic potential of enhancer activation, the researchers engineered human induced pluripotent stem cells carrying CHD8 or SCN2A mutations into two advanced laboratory platforms: two-dimensional cultures of human excitatory neurons and three-dimensional cortical organoids, self-organizing clusters of brain-like tissue that recapitulate early human cortical assembly.
The results demonstrated targeted molecular and functional rescue across both genetic models:
- Normalizing CHD8 Neurodevelopment: Activating the healthy CHD8 enhancer curbed the characteristic abnormal overgrowth seen in CHD8-mutant cortical organoids, promoted proper neuronal maturation, and shifted dysregulated downstream gene networks back toward typical expression baselines.
- Rescuing SCN2A Electrophysiology: In SCN2A-deficient neurons, boosting the functional allele restored a substantial portion of normal neuronal electrical firing and excitability, though certain fine-grained electrophysiological properties normalized only in specific genetic backgrounds.
- Built-In Biological Safety: Crucially, the treatment elevated gene output solely in cells harboring the mutation; healthy control cells exhibited no artificial spike in expression, and adjacent genes on the chromosome remained undisturbed.
“What stands out to us is that the approach acted only in cell lines carrying the mutation and left healthy cell lines alone,” noted first author Dr. George Chen, a former postdoctoral fellow in the Geschwind lab and current assistant professor of neurology at Children’s Hospital of Los Angeles. “That kind of specificity matters for any future therapy. We are still a long way from the clinic, and there is a lot of work ahead on delivery and timing, but these findings provide hope and give us a clear direction.”
Timing, Delivery, and Broader Neurodevelopmental Potential
The study also revealed that developmental timing plays a decisive role: enhancer activation yielded the strongest cellular rescue when applied during specific developmental windows, underscoring the dynamic nature of chromatin accessibility as neurons mature.
While the authors caution that the work represents an early-stage proof of concept conducted entirely in vitro, and that translating CRISPR enhancer therapies to patients will require overcoming major blood-brain barrier delivery hurdles and establishing efficacy beyond early embryonic windows, the implications extend far beyond CHD8 and SCN2A.
Because hundreds of neurodevelopmental and psychiatric conditions stem from single-copy gene loss, harnessing the genome’s natural regulatory dials could provide a versatile blueprint for precision molecular medicine.
Questions and Answers
How does this new CRISPR approach differ from traditional gene therapy?
Traditional gene therapy often attempts to replace a broken gene or permanently force it to stay switched on, which can cause toxic overexpression. Instead, the UCLA team used a modified CRISPR tool aimed at DNA “enhancers”, natural regulatory switches that control when and how strongly a gene operates, to gently boost the activity of the cell’s existing healthy gene copy within safe biological limits.
What improvements did researchers see in the lab-grown brain models?
In human cortical organoids with CHD8 mutations, boosting the healthy gene copy reduced abnormal tissue overgrowth and helped neurons mature properly. In neurons with SCN2A mutations, the approach restored normal electrical firing activity.
Why is this treatment considered promising for safety?
The CRISPR enhancer treatment only boosted gene activity in cells carrying the autism-linked mutation, leaving healthy cells and neighboring genes completely unchanged. Because it relies on existing natural gene regulation, it avoids the dangerous side effects of excessive protein production.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this autism Research:
- Media Contact: Nicola Burghall
- Source: UCLA
- Image Credit: Image credited to Neuroscience News
- Original Research is Open Access: Nature Neuroscience (Nov 13, 2026). “Enhancer-targeted CRISPR-A rescues haploinsufficiency and mutant phenotypes in organoid models of autism.” Authors: George T. Chen, Gayatri Nair, Aubrey J. Osorio, Sandra M. Holley, Kimiya Ghassemzadeh, Yixuan Zhou, Jose Gonzalez, Jacqueline M. Martin, Congyi Lu, Neville E. Sanjana, Carlos Cepeda & Daniel H. Geschwind.
- DOI: 10.1038/s41593-026-02504-9
Abstract
Enhancer-targeted CRISPR-A rescues haploinsufficiency and mutant phenotypes in organoid models of autism
Autism spectrum disorder (ASD) is a highly heritable condition with diverse clinical presentations. Approximately 15% of the genetic susceptibility of ASD is imparted by de novo haploinsufficient mutations of major effect.
We mapped enhancers of two high-confidence autism genes, CHD8 and SCN2A, and used CRISPR-based gene activation targeting enhancers (eCRISPR-A) in human pluripotent stem cell (hPSC)-derived excitatory neurons and cerebral forebrain organoids to correct the effects of haploinsufficiency, taking advantage of the presence of a wild-type allele of each gene and endogenous gene regulation.
Here we show that eCRISPR-A induced a sustained increase in CHD8 and SCN2A expression specifically in mutant neurons and cortical organoids, with rescue of gene expression levels and mutation-associated phenotypes, including gene expression and physiology.
These data support gene activation via targeting enhancers of haploinsufficient genes as a therapeutic intervention in ASD and other neurodevelopmental disorders.
